KRAS and neoplasm: Our results also demonstrated that docetaxel followed by gefitinib (D→G) was significantly superior to other modes in regard to the anti-tumor effects not only in EGFR mutant and K-ras WT PC-9 cells, but also in EGFR WT and K-ras mutant A549 cells.